BEAM•benzinga•
The FDA Has Granted Orphan Drug Designation To Beam Therapeutics' Beam-101, An Investigational Genetically Modified Cell Therapy For Sickle Cell Disease
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 3, 2025 by benzinga